Cipla arm secures marketing rights for cancer drug in US Industry-The Economic Times — August 10, 2018 comments off Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.
Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.